Toggle navigation
Home
Menu
Phenotypes
Genotypes
Strains
Panels, Populations
QTL Archive
Protocols
Contributors
Phenotyping procedures
Behavior tests
Drug and diet studies
Pathogen and challenge studies
Ontologies
Aging studies
Molecular studies
Replicability analysis
Multi-measure study designs
What's new
Submit data
Downloads
MPD data API
Data changelog
Tools demo
About
MyMPD
My Collection
Sign In / Register
Search
Examples
Phenotype measures in
Xenakis1
associated with
ontology
term
MP:0005266 'abnormal metabolism'
List measures from all projects
MGI
Broaden
Navigate ontologies
All measures in this list are mapped to the
ontology descendants
of MP:0005266. None are mapped to MP:0005266 directly.
MP:0012693 abnormal haloperidol metabolism
This MP term has been mapped to these MPD phenotype measurements to help users find relevant data. It should be noted that MPD measurements typically have a mixture of high-end, low-end and "normal" readings.
Filter Table Results
Data set
Clear All
Xenakis1
(10)
Procedure / Protocol
Clear All
behavior observation
(4)
drug and metaboli...
(1)
inclined screen test
(1)
open field test
(4)
Treatment
Clear All
haloperidol
(10)
Panel
Clear All
CC RIX
(10)
Sex
Clear All
both
(10)
Help / filtering
Sort/
Pick
Data set
Procedure / Protocol
Treatment
Phenotype Measure / Variable (click to view)
Panel
No. of Strains
Sex
Age
Sample Size (Avg)
Year
Xenakis1:13
Xenakis1
inclined screen test
haloperidol
latency to move all four paws (extrapyramidal symptoms), treatment group [s]
latency_Rx
111156
pre-treatment post-treatment
CC RIX
73
both
7-9wks
N=3
2020
Xenakis1:17
Xenakis1
open field test
haloperidol
distance traveled, 30 min test, treatment group [cm]
distance_Rx
111160
pre-treatment post-treatment
CC RIX
73
both
7-13wks
N=3
2020
Xenakis1:21
Xenakis1
open field test
haloperidol
vertical activity (beam breaks), 30 min test, treatment group [n]
vertical_Rx
111164
pre-treatment post-treatment
CC RIX
73
both
7-13wks
N=3
2020
Xenakis1:25
Xenakis1
open field test
haloperidol
time spent in center of arena, 30 min test, treatment group [s]
center_Rx
111168
pre-treatment post-treatment
CC RIX
73
both
7-13wks
N=3
2020
Xenakis1:29
Xenakis1
open field test
haloperidol
stereotypy activity (beam breaks), 30 min test, treatment group [n]
stereotypy_Rx
111172
pre-treatment post-treatment
CC RIX
73
both
7-13wks
N=3
2020
Xenakis1:31
Xenakis1
behavior observation
haloperidol
subtle vacuous chewing movements, 15 min test, treatment group, post-treatment [n]
subtle_vcm_Rx_post
111174
CC RIX
73
both
11-13wks
N=5
2020
Xenakis1:32
Xenakis1
behavior observation
haloperidol
overt vacuous chewing movements, 15 min test, treatment group, post-treatment [n]
overt_vcm_Rx_post
111175
CC RIX
73
both
11-13wks
N=5
2020
Xenakis1:33
Xenakis1
behavior observation
haloperidol
tongue protrusions, 15 min test, treatment group, post-treatment [n]
tongue_Rx_post
111176
CC RIX
73
both
11-13wks
N=5
2020
Xenakis1:34
Xenakis1
behavior observation
haloperidol
jaw tremors, 15 min test, treatment group, post-treatment [n]
jawtremor_Rx_post
111177
CC RIX
73
both
11-13wks
N=5
2020
Xenakis1:36
Xenakis1
drug and metabolite quantification
haloperidol
plasma haloperidol concentration, treatment group, post-treatment [ng/dL]
haloperidol_conc_post
111179
CC RIX
53
both
11-13wks
N=2
2020
All boxes
Work with selected measures
Or, add these measures to your collection.
no folder
put them in new folder
FUNDING
CITING MPD
UNITS
CHANGE LOG
CONTACT
HELP | FEEDBACK
TERMS OF USE | PRIVACY POLICY
RESEARCH RESOURCES
MOUSE GENOME INFORMATICS
© 2001-2024 THE JACKSON LABORATORY